Therapy will cost Rs 35 to 50 lakh. India sees around 1.20 lakh new blood cancer cases and over 70,000 deaths annually from leukemia, lymphoma & multiple myeloma.
Therapy developed by IIT-Bombay spin-off company ImmunoACT approved for relapsed-refractory B-cell lymphoma, leukemia, to be available in around 20 govt & pvt hospitals across major cities.
Pharma giant Bristol Myers Squibb & partner 2seventy bio say they've successfully tested the treatment, which is aimed at stimulating patient’s immune system to act more efficiently.
This is the game every nation is now learning to play. Some are finding new allies or seeing value among nations where they’d seen marginal interest. The starkest example is India & Europe.
COMMENTS